Sulfur Attached Directly To Urea Nitrogen By Nonionic Bonding Patents (Class 514/592)
  • Patent number: 9511075
    Abstract: The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: December 6, 2016
    Assignees: The University of Maryland, Baltimore, The United States of America as Represented by the Dept. of Veterans Affairs
    Inventor: J. Marc Simard
  • Patent number: 8980952
    Abstract: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: March 17, 2015
    Assignees: University of Maryland, Baltimore, The United States of America as represented by the Dept. of Veterans Affairs
    Inventors: J. Marc Simard, Mingkui Chen
  • Publication number: 20150010638
    Abstract: It is an object of the present invention to provide a method for improving the solubility of a poorly-soluble substance, which is capable of increasing the solubility of substantially all poorly-soluble substances. This is a method comprising coating the surface of a poorly-soluble substance particle with microparticles of a calcium compound such as calcium phosphate or calcium carbonate, and at least one selected from a pH adjuster and a surfactant, by applying mechanical energy thereto.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Inventors: Shuji Sakuma, Keiichiro Kikukawa, Ryosuke Miyasaka
  • Publication number: 20140235564
    Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Inventors: J. Marc Simard, Mingkui Chen
  • Publication number: 20140221286
    Abstract: It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 7, 2014
    Inventors: Luiz Belardinelli, Arvinder Dhalla
  • Publication number: 20140200516
    Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: ABBOTT LABORATORIES
    Inventor: Harry A. DUGGER, III
  • Publication number: 20140023615
    Abstract: The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer.
    Type: Application
    Filed: March 29, 2012
    Publication date: January 23, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Stephen I-Hong Hsu
  • Patent number: 8569377
    Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: October 29, 2013
    Assignees: The United States of America as Represented by the Department of Veteran Affairs, University of Maryland, Baltimore
    Inventor: J. Marc Simard
  • Publication number: 20130184293
    Abstract: The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders.
    Type: Application
    Filed: December 12, 2012
    Publication date: July 18, 2013
    Applicants: UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
  • Publication number: 20130123172
    Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 16, 2013
    Applicant: DIAPIN THERAPEUTICS LLC
    Inventor: DIAPIN THERAPEUTICS LLC
  • Publication number: 20130053446
    Abstract: A manufacturing device capable of creating individualized dosages of pharmaceutical preparations in which a metering system and a means of performing non-destructive chemical analysis of individual manufactured units are controlled by a microprocessor to precisely control the content and structure of each individual unit.
    Type: Application
    Filed: November 6, 2010
    Publication date: February 28, 2013
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Fernando J. Muzzio, Pavlo Takhistov, Bozena B. Michniak-Kohn
  • Publication number: 20130029996
    Abstract: The present invention relates to a composition containing at least one polyphenol, at least one polyethylene glycol and/or a functional equivalent and at least one glycol ether and/or a functional equivalent for application as a medicinal product. The composition according to the invention can also be used as a food supplement or nutraceutical.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 31, 2013
    Inventors: Remy Burcelin, Eric Seree
  • Patent number: 8318810
    Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: November 27, 2012
    Assignees: University of Maryland, Baltimore, The United States of America as represented by the Department of Veterans Affairs
    Inventors: J. Marc Simard, Mingkui Chen
  • Publication number: 20120294936
    Abstract: The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.
    Type: Application
    Filed: November 12, 2010
    Publication date: November 22, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Peter Timmins
  • Publication number: 20120225782
    Abstract: Compounds having the following generic formula are disclosed.
    Type: Application
    Filed: April 11, 2012
    Publication date: September 6, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Nneka T. Breaux, Michael R. Loso, Timothy C. Johnson, Jonathan M. Babcock, Benjamin M. Nugent, Timothy P. Martin, Annette V. Brown, Ronald Ross, JR., William C. Lo, Matthias S. Ober
  • Publication number: 20120149639
    Abstract: The invention relates to a method to reduce the hypoglycemic events, especially severe hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Inventors: Börk Balkan, David Grenville Holmes, Thomas Edward Hughes, Edwin Bernard Villhauer
  • Publication number: 20120121707
    Abstract: A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle.
    Type: Application
    Filed: November 11, 2010
    Publication date: May 17, 2012
    Applicant: National Taiwan University
    Inventors: Yan-Ping Chen, Pai-Ching Lin
  • Publication number: 20110311594
    Abstract: The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect.
    Type: Application
    Filed: June 21, 2011
    Publication date: December 22, 2011
    Inventors: Shou-Chiung Chen, Shao-Ming Lee, Chaur-Ming Jan
  • Publication number: 20110293556
    Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.
    Type: Application
    Filed: August 8, 2011
    Publication date: December 1, 2011
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Stuart A. LIPTON, Daniel EINHORN
  • Patent number: 7956041
    Abstract: The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: June 7, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Katsumi Maezono, Nozomu Ishida, Koji Ohsumi, Hiroyuki Matsueda, Toshihiro Hatanaka, Ryusuke Hirama, Yoko Kageyama, Nobuo Kondo
  • Publication number: 20110059175
    Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.
    Type: Application
    Filed: April 10, 2007
    Publication date: March 10, 2011
    Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENT
    Inventors: Sandrien Janssens, Guy Van Den Mooter
  • Patent number: 7872048
    Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: January 18, 2011
    Assignee: University of Maryland, Baltimore
    Inventor: J. Marc Simard
  • Publication number: 20100273703
    Abstract: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed.
    Type: Application
    Filed: June 16, 2010
    Publication date: October 28, 2010
    Applicant: Daiichi Sankyo, Inc.
    Inventor: Michael R. Jones
  • Patent number: 7820158
    Abstract: Initiator polymers having an initiator group and a ligand group are provided. The initiator polymers are capable of specifically binding to a receptor on a surface. Using a macromer system, the initiator polymers are useful for the formation of a polymeric matrix on the surface of a material. In particular, initiator polymers are provided that have specificity to pancreatic ? cells and can be used to encapsulate cells for transplantation and the treatment of diabetes.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: October 26, 2010
    Assignee: SurModics, Inc.
    Inventors: Stephen J. Chudzik, Dale G. Swan
  • Publication number: 20100261645
    Abstract: The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Application
    Filed: March 16, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Elisabeth DEFOSSA, Thomas KLABUNDE, Viktoria DIETRICH, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK
  • Publication number: 20100261644
    Abstract: The invention relates to (cyclopropylphenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Application
    Filed: March 16, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Elisabeth DEFOSSA, Thomas KLABUNDE, Viktoria DIETRICH, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK
  • Patent number: 7807663
    Abstract: A pharmaceutical composition for preventing and/or treating diabetes, diabetic complication, hyperinsulinemia, disorders of glucose metabolism or obesity, comprising a combination of the following compound, analogues or pharmaceutically acceptable salts thereof with a hypoglycemic agent.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: October 5, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takao Ikenoue, Yoko Kageyama, Yukio Iino, Nobuo Kondo
  • Publication number: 20100247548
    Abstract: Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: June 9, 2010
    Publication date: September 30, 2010
    Applicant: Alcon Research, Ltd.
    Inventors: Allan R. Shepard, Debra L. Fleenor, Abbot F. Clark, Najam A. Sharif
  • Patent number: 7803786
    Abstract: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: September 28, 2010
    Assignees: Transform Pharmaceuticals, Inc., University of South Florida
    Inventors: Jennifer McMahon, Matthew Peterson, Michael J. Zaworotko, Tanise Shattock, Magali Bourghol Hickey
  • Publication number: 20100190686
    Abstract: The present invention relates to the discovery of polypeptide biomarkers excreted into the blood stream (serum or plasma) and/or urine from adipocytes and their use to determine the existence of metabolic syndrome (prediabetic) and/or diabetic conditions (including type 2 diabetes) including insulin resistance and/or glucose intolerance, their use to monitor the state of metabolic syndrome or diabetes toward a state of control and/or cure of the disease state or condition and their use to monitor the long-term health of the patient by determining the existence of metabolic syndrome (prediabetic conditions insulin resistance and/or glucose intolerance) or the existence of type 2 diabetes and to identify potential antidiabetes agents. Methods of identifying potential agents to be used in the treatment of metabolic syndrome and/or type2 diabetes and assays for assisting in the diagnosis of metabolic syndrome and/or type 2 diabetes are additional aspects of the invention.
    Type: Application
    Filed: June 23, 2008
    Publication date: July 29, 2010
    Applicant: The University of Georgia Research Foundation
    Inventors: Robert L. Wells, Jae-min Lin, Dorothy Hausman
  • Publication number: 20100143347
    Abstract: The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example
    Type: Application
    Filed: January 11, 2008
    Publication date: June 10, 2010
    Inventor: J. Marc Simard
  • Publication number: 20100092469
    Abstract: The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example.
    Type: Application
    Filed: February 8, 2008
    Publication date: April 15, 2010
    Inventors: J. Marc Simard, Vladimir Gerzanich
  • Publication number: 20100056444
    Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.
    Type: Application
    Filed: October 11, 2007
    Publication date: March 4, 2010
    Inventors: Sven Martin Jacobson, Robert Ang
  • Patent number: 7655696
    Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: February 2, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Publication number: 20090311325
    Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.
    Type: Application
    Filed: April 10, 2007
    Publication date: December 17, 2009
    Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENT
    Inventors: Sandrien Janssens, Guy Van Den Mooter
  • Publication number: 20090221424
    Abstract: Compounds having the following generic formula are disclosed.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 3, 2009
    Applicant: Dow AgroSciences LLC
    Inventors: Nneka T. Breaux, Michael R. Loso, Timothy C. Johnson, Jonathan M. Babcock, Benjamin M. Nugent, Timothy P. Martin, Annette V. Brown, Ronald Ross, JR., William C. Lo, Matthias S. Ober
  • Publication number: 20090197836
    Abstract: A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.
    Type: Application
    Filed: August 20, 2007
    Publication date: August 6, 2009
    Inventors: Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
  • Publication number: 20090181980
    Abstract: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.
    Type: Application
    Filed: May 9, 2007
    Publication date: July 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Meenakshi Balganesh, Santosh Nandan
  • Publication number: 20090137680
    Abstract: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
    Type: Application
    Filed: August 29, 2008
    Publication date: May 28, 2009
    Inventors: J. Marc Simard, Mingkui Chen
  • Publication number: 20090061031
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPAR?2, LPL and ?P2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual.
    Type: Application
    Filed: July 9, 2007
    Publication date: March 5, 2009
    Inventors: Sylvia Lee-Huang, Paul L. Huang, Philip Lin Huang, Dawei Zhang, John Z.H. Zhang, Young Tae Chang, Jae Wook Lee, Ju Bao, Yongtao Sun
  • Publication number: 20080262088
    Abstract: Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and/or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for improving or at least stabilizing pancreatic function(s) and for the prevention and/or treatment of metabolic syndrome and its components. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in patients in need thereof, including diabetic patients.
    Type: Application
    Filed: December 21, 2007
    Publication date: October 23, 2008
    Inventors: Wendy HAUCK, Pavel Hamet
  • Publication number: 20080260824
    Abstract: The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner. Also described herein are polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers.
    Type: Application
    Filed: August 29, 2005
    Publication date: October 23, 2008
    Applicant: Spherics, Inc.
    Inventors: Avinash Nangia, Jules Jacob, Peyman Moslemy
  • Publication number: 20080255030
    Abstract: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.
    Type: Application
    Filed: August 6, 2007
    Publication date: October 16, 2008
    Inventors: Xing-Xian Yu, Sanjay Bhanot
  • Publication number: 20080248099
    Abstract: The present invention provides a use of an insulin for the manufacture of a medicament for treating or preventing diseases or disorders of adult brain. Also provided is a method for treating or preventing diseases or disorders of adult brain by administering an effective amount of an insulin to the brain. The diseases or disorders of adult brain are associated with tissue shrinkage or atrophy. The amount of the insulin administered is preferably from 0.001 Units per kg body weight per day up to 10 Units per kg body weight per day.
    Type: Application
    Filed: November 10, 2006
    Publication date: October 9, 2008
    Inventor: Douglas N. Ishii
  • Publication number: 20080220092
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 11, 2008
    Applicant: CHRONO THERAPEUTICS, INC.
    Inventors: Guy Dipierro, Steven A. Giannos
  • Patent number: 7319170
    Abstract: A class of N-cyclohexylaminocarbonyl benzenesulfonamide derivatives are agonists or partial agonists or antagonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: January 15, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Soumya P. Sahoo, Hiroo Koyama, Daniel J. Miller
  • Patent number: 7285574
    Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: October 23, 2007
    Assignee: University of Maryland, Baltimore
    Inventors: J. Marc Simard, Mingkui Chen
  • Patent number: 7241756
    Abstract: A method for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a dipeptidyl peptidase IV inhibitor and another antidiabetic agent, to a mammal in need thereof.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: July 10, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Jonathan Robert Sanders Arch, James Martin Lenhard
  • Patent number: 6992106
    Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: January 31, 2006
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
  • Patent number: 6951844
    Abstract: New thyroid receptor ligands are provided which have the general formula I wherein R1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted C3-7 cycloalkyl; R2 and R3 are each independently hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted C3-6 cycloalkyl, wherein at least one of R2 and R3 is other than hydrogen; R4 is a carboxylic acid selected from the group consisting of (CH2)nCOOH, (CH)2COOH, NHCO(CH2)nCOOH, CONH(CH2)nCOOH and NH(CH2)mCOOH; n is an integer from 0 to 4; and m is an integer from 1 to 4. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: October 4, 2005
    Assignee: Bristol Myers Squibb Company
    Inventor: Jon J. Hangeland